Small-cell neuroendocrine carcinoma of the prostate: Are heterotransplants a better experimental model?

Asian Journal of Andrology

Volumn 12, Issue 3, 2010, Pages 308-314

  Lopez Barcons, Lluis A ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heterotransplant; Nude mice; Prostate; Small cell neuroendocrine carcinoma; Xenotransplant

Indexed keywords

ANDROGEN RECEPTOR; TUMOR MARKER;

CANCER MODEL; CELL CULTURE; CELL CYCLE; CELL INTERACTION; CYTOLOGY; DNA CONTENT; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; KARYOTYPE; METASTASIS; NEUROSECRETION; NONHUMAN; PROSTATE CARCINOMA; REVIEW; SMALL CELL NEUROENDOCRINE PROSTATE CARCINOMA; STROMA CELL; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; CARCINOMA, NEUROENDOCRINE; CELL CYCLE; DISEASE MODELS, ANIMAL; DNA, NEOPLASM; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROTOPIC; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952055979     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.68     Document Type: Review

References (26)

1. American Cancer Society (ACS). Cancer Facts and Figures 2008.
2. Helpap B, Kollermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 1999;62:133-8.
3. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
4. Okada H, Shirakawa T, Miyake H, Gotoh A, Fujisawa M, et al. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate 2003;56:231-8.
5. Morton CL, Houghton PJ. Establishment of human tumor xenograts in immunodefcient mice. Nat Protoc 2007;2:247-50.
6. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-73.
7. Aubert C, Rougé F, Galindo JR. Tumorigenicity of human malignant melanocytes in nude mice in relation to their differentiation in vitro. J Natl Cancer Inst 1980;64:1029-40.
8. Li H, Fu X, Zhang L, Sun T, Wang J. In vivo dedifferentiation of human epidermal cells. Cell Biol Int 2007;31:1436-41.
9. Steiner MS. Molecular Biology of Prostate Growth Regulation. In: Lepor H, editor. Prostatic Diseases. Philadelphia, W. B. Saunders Co.; 2002. p41-57.
10. Taylor RA, Risbridger GP. Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets 2008;8:490-7.
11. Presnell SC, Werdin ES, Maygarden S, Mohler JL, Smith GJ. Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 2001;159:855-60.
12. van Haaften-Day C, Raghavan D, Russell P, Wills EJ, Gregory P, et al. Xenografted small cell undifferentiated cancer of prostate. Possible common origin with prostatic adenocarcinoma. Prostate 1987;11:271-9.
13. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, et al. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res 2000;60:6563-7.
14. True LD, Buhler K, Quinn J, Williams E, Nelson PS, et al. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002;161:705-15.
15. Reid L, Sato G. Development of transplantable tumors of human prostate gland implanted in nude mice. J Cell Biol 1976;70:860a.
16. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982;21:6188-93.
17. Jelbart ME, Russell PJ, Russell P, Wass J, Fullerton M, et al. Site-specifc growth of the prostate xenograft line UCRU-PR-2. Prostate 1989;14:163-75.
18. Gavish Z, Pinthus JH, Barack V, Ramon J, Nagler A, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002;51:73-83.
19. Pittman S, Russell PJ, Jelbart ME, Wass J, Raghavan D. Flow cytometry and karyotypic analysis of a primary small cell neuroendocrine carcinoma of the prostate: a xenografted cell line. Cancer Genet Cytogenet 1987;26:165-9.
20. Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chrom. Cancer 2002;35:66-73.
21. Jelbart ME, Russell PJ, Fullerton M, Russell P, Funder J, et al. Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Mol Cell Endocrinol 1988;55:167-72.
22. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003;55:55-64.
23. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, et al. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res 2002;8:1003-7.
24. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, et al. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 2006;8:862-78.
25. Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, et al. Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. Prostate 2008;68:530-9.
26. Yang J, Liu A, Dougherty C, Chen X, Guzman R, et al. Beware of contaminating mouse cells in human xenografts from nude mice. Anticancer Res 2000;20:1635-9.